Bacteria-Based immunotherapy targets pancreatic tumors in first human test
Disease control
Not yet recruiting
Researchers are testing a new immunotherapy called Lm-LLO-TT in adults with advanced pancreatic ductal adenocarcinoma that has already been treated with chemotherapy. Lm-LLO-TT uses a weakened form of Listeria bacteria engineered to carry a tetanus toxoid antigen, aiming to spark…
Phase 1 • Sponsor: Loki Therapeutics, Inc. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC